Compare LW & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LW | ERAS |
|---|---|---|
| Founded | 1950 | 2018 |
| Country | United States | United States |
| Employees | 10100 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.5B |
| IPO Year | 2016 | 2021 |
| Metric | LW | ERAS |
|---|---|---|
| Price | $46.09 | $21.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $44.14 | $12.08 |
| AVG Volume (30 Days) | 2.7M | ★ 4.9M |
| Earning Date | 04-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 1.29 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.62 | $1.06 |
| 52 Week High | $67.07 | $19.78 |
| Indicator | LW | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 77.30 |
| Support Level | $39.70 | $1.98 |
| Resistance Level | $52.05 | N/A |
| Average True Range (ATR) | 1.62 | 1.49 |
| MACD | 0.72 | 0.29 |
| Stochastic Oscillator | 99.30 | 99.08 |
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.